Why Gilead Sciences Remains A Buy After A 40% Rally
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
Healio8 小时
Q&A: How can implementation of long-acting injectables for HIV prevention be improved?
A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables ...
来自MSN12 小时
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
BLUE Stock Plunges on Update
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...